<DOC>
	<DOCNO>NCT00040950</DOCNO>
	<brief_summary>RATIONALE : Monoclonal antibody rituximab locate cancer cell either kill deliver cancer-killing substance without harm normal cell . Biological therapy CpG 7909 use different way stimulate immune system stop cancer cell grow . Combining CpG 7909 rituximab may kill cancer cell . PURPOSE : Phase I trial study effectiveness CpG 7909 plus rituximab treating patient relapse refractory non-Hodgkin 's lymphoma .</brief_summary>
	<brief_title>Biological Therapy Plus Monoclonal Antibody Therapy Treating Patients With Relapsed Refractory Non-Hodgkin 's Lymphoma</brief_title>
	<detailed_description>OBJECTIVES : - Determine maximum tolerate dose subcutaneous IV CpG 7909 administer rituximab patient relapse refractory B-cell non-Hodgkin 's lymphoma . - Determine safety tolerability regimen patient . - Determine disease response patient treat regimen . OUTLINE : This multicenter , dose-escalation study CpG 7909 . Patients sequentially assign 1 2 treatment group . - Group A : Patients receive rituximab IV 4-5 hour follow CpG 7909 IV 2 hour day 1 . Courses repeat weekly 4 week . - Group B : Patients receive rituximab follow CpG 7909 subcutaneously day 1 . Courses repeat weekly 4 week . Cohorts 3-6 patient receive escalate dos CpG 7909 maximum tolerate dose ( MTD ) determine . The MTD define dose precede least 2 3 2 6 patient experience dose-limiting toxicity . Patients follow 4 week . PROJECTED ACCRUAL : A total 6-48 patient ( 3-24 per treatment group ) accrue study .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm CD20+ Bcell nonHodgkin 's lymphoma ( NHL ) CD20 positive immunohistochemistry flow cytometry Relapsed refractory disease Bidimensionally measurable disease Sole site measurable disease within previously irradiate field allow provided disease progression site No preexisting ascites pleural effusion No know CNS involvement NHL PATIENT CHARACTERISTICS : Age : 18 Performance status : ECOG 02 Life expectancy : More 3 month Hematopoietic : Neutrophil count least 1,000/mm3 Platelet count least 50,000/mm3 Hepatic : Bilirubin le 2 mg/dL Transaminase le 2 time upper limit normal No hepatitis B C Renal : Creatinine le 2 mg/dL Cardiovascular : No significant cardiovascular disease No New York Heart Association class III congestive heart failure No myocardial infarction within past 6 month No unstable angina No uncontrolled atrial ventricular cardiac arrhythmia Pulmonary : No concurrent significant pulmonary disease Other : HIV negative No acute infection require antibiotic No fever 38.2 degree C within past 3 day No malignancy within past 5 year except basal cell noninvasive squamous cell skin cancer carcinoma situ cervix No preexisting autoimmune disease antibodymediated disease , include : Systemic lupus erythematosus Rheumatoid arthritis Multiple sclerosis Sjogren 's syndrome Autoimmune thrombocytopenia Controlled thyroid disease allow Concurrent autoantibody without clinical autoimmune disease allow No history allergic reaction attribute compound similar composition study drug No medical history , include laboratory result , would preclude study No suspect confirm poor compliance mental instability would preclude study Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : Biologic therapy : No prior allogeneic transplantation More 30 day since prior hematopoietic growth factor ( e.g. , filgrastim ( GCSF ) epoetin alfa ) More 30 day since prior immunotherapy More 90 day since prior monoclonal antibody monotherapy patient unresponsive treatment ( 30 day patient respond treatment subsequently relapse ) No concurrent biological agent No concurrent hematopoietic growth factor ( e.g. , GCSF epoetin alfa ) Chemotherapy : More 30 day since prior chemotherapy No concurrent chemotherapy Endocrine therapy : More 30 day since prior systemic corticosteroid No concurrent systemic corticosteroid Radiotherapy : See Disease Characteristics More 30 day since prior radiotherapy No concurrent radiotherapy Surgery : Not specify Other : Recovered prior therapy At least 6 month since prior coronary angioplasty More 30 day since prior immunosuppressant More 30 day since prior participation investigational drug study No concurrent immunosuppressants No concurrent anticoagulants except aspirin dos great 325 mg/day No concurrent anticancer therapy No concurrent investigational agent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2003</verification_date>
	<keyword>recurrent grade 1 follicular lymphoma</keyword>
	<keyword>recurrent grade 2 follicular lymphoma</keyword>
	<keyword>recurrent grade 3 follicular lymphoma</keyword>
	<keyword>recurrent adult diffuse small cleave cell lymphoma</keyword>
	<keyword>recurrent adult diffuse mixed cell lymphoma</keyword>
	<keyword>recurrent adult diffuse large cell lymphoma</keyword>
	<keyword>recurrent adult immunoblastic large cell lymphoma</keyword>
	<keyword>recurrent adult lymphoblastic lymphoma</keyword>
	<keyword>recurrent adult Burkitt lymphoma</keyword>
	<keyword>recurrent mantle cell lymphoma</keyword>
	<keyword>recurrent marginal zone lymphoma</keyword>
	<keyword>recurrent small lymphocytic lymphoma</keyword>
	<keyword>extranodal marginal zone B-cell lymphoma mucosa-associated lymphoid tissue</keyword>
	<keyword>nodal marginal zone B-cell lymphoma</keyword>
	<keyword>splenic marginal zone lymphoma</keyword>
</DOC>